에보텍 (EVO) 주가

에보텍(EVO)는 NASDAQ에 상장된 Healthcare · Drug Manufacturers - Specialty & Generic 기업입니다. 현재가 $1.60 (-4.19%), 시가총액 $1.09B, 52주 최저~최고 $2.31 ~ $4.73.

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center fo

핵심 지표

• 현재가: $1.60 (-4.19%)
• 시가총액: $1.09B
• 52주 최저~최고: $2.31 ~ $4.73
• 섹터: Healthcare
• 산업: Drug Manufacturers - Specialty & Generic
• 거래소: NASDAQ

에보텍의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

에보텍 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 3.6667

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.33
• 순이익률: -0.26%
• 영업이익률: -0.30%

자주 묻는 질문